Verseon Corporation Verseon presents HAE program at Biotech Showcase

TIDMVSN

Verseon Corporation

10 January 2018

Press release January 10, 2018

Verseon Corporation

("Verseon" or the "Company")

Verseon presents hereditary angioedema program at Biotech Showcase

Fremont, Calif.-Verseon, a technology-based pharmaceutical company employing a computer-driven platform to develop a diverse drug pipeline, presented preclinical results in its hereditary angioedema (HAE) program at the 2018 Biotech Showcase in San Francisco yesterday, January 9. The data show that Verseon's plasma kallikrein inhibitors are well-suited as oral treatments for this rare genetic disease.

HAE is characterized by recurring episodes of severe swelling, which can be life-threatening if they affect the airways. The disease is caused by a genetic defect which results in reduced activity of the C1-inhibitor protein, leading to the overactivation of several serine proteases and subsequent inflammation and edema. To treat this disease, Verseon is developing oral small-molecule inhibitors of plasma kallikrein, a serine protease central to the HAE pathway. The Company's class of drug candidates spans multiple different chemotypes that show excellent in vitro potency and are selective against other related serine proteases.

In contrast to currently marketed therapeutics, which rely on intravenous or subcutaneous injections, Verseon's drug candidates demonstrate pharmacokinetic exposure suitable for convenient oral dosing. Dr. David Kita, Verseon's Vice President of R&D, also presented promising preclinical results that show strong reduction of swelling after oral administration in a well-established HAE efficacy model.

"We are very encouraged by these results," said Dr. Kita. "We started the HAE program only recently, and have already demonstrated that our oral plasma kallikrein inhibitors have great potential for the effective management of HAE attacks. The next milestone this year will be the nomination of our first development candidate for advancement into clinical trials."

About Verseon's hereditary angioedema program

Verseon is developing small-molecule plasma kallikrein inhibitors for the treatment of hereditary angioedema. In vitro, the candidates potently inhibit plasma kallikrein and show selectivity against a broad range of related serine proteases. Lead compounds have shown efficacy in a well-established HAE efficacy model as well as pharmacokinetics suitable for oral dosing.

About Verseon

Verseon Corporation (www.verseon.com, AIM: VSN) is a technology-based pharmaceutical company that pairs a proprietary, computational drug discovery platform with a comprehensive in-house chemistry and biology workflow to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology. The anticoagulation program is scheduled to enter phase I clinical trials in 2018.

-Ends-

For further information, please contact

 
 Verseon Corporation                  www.verseon.com 
                                      +1 (510) 225 
 Sebastian Wykeham / Tina Schlafly     9000 
 
 Cenkos Securities (NOMAD and 
  Joint Broker) 
                                       +44 (0) 20 
 Neil McDonald / Beth McKiernan         7397 8900 
 
 Cantor Fitzgerald Europe (Joint 
  Broker) 
 Marc Milmo / Phil Davies /           +44 (0) 20 
  Callum Butterfield                   7894 7000 
 

For financial and business media enquiries, please contact

 
 Buchanan Communications Ltd 
  (PR Advisers) 
 Henry Harrison-Topham / Jamie    +44 (0) 20 
  Hooper                           7466 5000 
 

For trade and pharma media enquiries, please contact

 
 Vane Percy & Roberts 
                         +44 (0) 1737 
 Simon Vane Percy         821 890 
 

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends, " "estimates," "plans," "will," "outlook," and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions, and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGMGGMRLFGRZM

(END) Dow Jones Newswires

January 10, 2018 02:00 ET (07:00 GMT)